Edition:
United States

CASI Pharmaceuticals Inc (CASI.OQ)

CASI.OQ on NASDAQ Stock Exchange Capital Market

3.06USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
153,845
52-wk High
$4.83
52-wk Low
$0.91

Summary

Name Age Since Current Position

Wei-Wu He

50 2013 Chairman of the Board

Ken Ren

56 2014 Chief Executive Officer, Director

Cynthia Hu

45 2008 Chief Operating Officer, General Counsel, Secretary

Sara Capitelli

48 2011 Vice President - Finance, Principal Accounting Officer

Rong Chen

2015 Chief Medical Officer

Tak Mak

69 2012 Director

Rajesh Shrotriya

73 2014 Director

James Huang

50 2013 Independent Director

Franklin Salisbury

59 2014 Independent Director

Y. Alexander Wu

51 2013 Independent Director

Biographies

Name Description

Wei-Wu He

Dr. Wei-Wu He, Ph.D., serves as an Chairman of the Board of CASI Pharmaceuticals, Inc. He was Executive Chairman of the Company from February 2012 to May 2013, and has since continued to serve as Chairman. Dr. He has served as the Chief Executive Officer and Chairman of OriGene Technologies, Inc. since 1995. He also is the founder and General Partner of Emerging Technology Partners, LLC, a life sciences focused venture fund established in 2000. From 1993 to 1996, Dr. He was a senior scientist at Human Genome Sciences. Prior to that he was a Research Fellow at Massachusetts General Hospital and at the Mayo Clinic. Dr. He received his Ph.D. from Baylor College of Medicine and MBA from The Wharton School of University of Pennsylvania. We believe that as a seasoned leader in the biotechnology industry and demonstrated financing and business acumen in both the United States and China, Dr. He adds valuable insight and expertise to the Board of Directors. Dr. He’s knowledge of the drug development process provides valuable insight to the Company. His leadership skills, strategic analysis, industry knowledge and substantial experience in the biotech sector give him the qualifications and skills to serve as a Director and the Chairman of the Company.

Ken Ren

Dr. Ken K. Ren, Ph.D., is Chief Executive Officer, Director of CASI Pharmaceuticals, Inc. Dr. Ren joined the Company in April 2012 as interim Chief Executive Officer, and after successful completion of the one-year interim period, was appointed Chief Executive Officer in April 2013, and in December 2014 was elected to the Board of Directors. Prior to joining the Company, from 2005-2012, Dr. Ren was the president of Accelovance (China), a subsidiary of Accelovance, Inc., which is a Maryland-based contract research organization. Prior to Accelovance, Dr. Ren was the founder of New Jersey-based AHT Inc., which merged with Novemed, a portfolio investment of a blue-chip public company in Hong Kong. He was a co-founder of the China Innovation Center for Life Science (U.S.A.) Corp., a New York-based consulting firm in partnership with the Chinese Ministry of Science and Technology which provided consulting services to health-care and pharmaceutical companies in both the U.S. and China. Over the past 15 years Dr. Ren has been involved in several U.S./China based start-up companies in pharmaceutical development or services. Dr. Ren was a research scientist at Pfizer from 1993–1995 and a Research Fellow at Rockefeller University from 1990–1993. He received his medical degree at the Shandong University School of Medicine in China in 1986 and a Ph.D. from State University of New York at Buffalo in 1990. Dr. Ren’s qualifications to serve on the Board of Directors include his extensive leadership experience and background in the healthcare and pharmaceutical industries, which make him well qualified to serve on our Board of Directors.

Cynthia Hu

Ms. Cynthia W. Hu, J.D., is Chief Operating Officer, General Counsel, Secretary of CASI Pharmaceuticals, Inc. Ms. Hu joined EntreMed in June 2006 as Vice President, General Counsel & Secretary and was appointed Chief Operating Officer in December 2008. Prior to joining EntreMed, from January 2000 to May 2006, Ms. Hu served as senior attorney for the corporate and finance practice group at Powell Goldstein LLP in Washington, DC, where she advised clients on all corporate matters, including complex public and private financings, mergers and acquisitions, SEC and regulatory compliance, and corporate governance and compliance. Before that, he served as counsel for ING Annuities (formerly Golden American Life Insurance Company) and an attorney with the law firms of Klehr, Harrison, Harvey & Branzburg, LLP and Littman & Krooks, LLP focusing on public corporate transactions, financings, mergers and acquisitions, and compliance with corporate and securities laws.

Sara Capitelli

Ms. Sara B. Capitelli, CPA, serves as Vice President - Finance, Principal Accounting Officer of CASI Pharmaceuticals, Inc. Ms. Capitelli joined EntreMed in January 2011 as Vice President, Finance and Principal Accounting Officer. Prior to joining EntreMed, from May 2010 to January 2011, Ms. Capitelli served as Controller for the Association for Financial Professionals in Bethesda, Maryland. From 1999-2008, she served as Senior Manager with Ernst & Young LLP, where she provided audit and consulting services for small public and private companies. Prior to that, she served as Director, Financial Planning and Reporting of Cable & Wireless USA, a wholly-owned subsidiary of Cable & Wireless plc. Ms. Capitelli holds a CPA license in both Maryland and Virginia. Ms. Capitelli received her Bachelor of Science, Business Administration – Accounting, from Bucknell University.

Rong Chen

Dr. Rong Chen M.D., Ph.D. is Chief Medical Officer of CASI Pharmaceuticals, Inc. Prior to joining CASI, Dr. Chen was Area Medical Director and Chief Medical Governance Officer at GSK China/ Hong Kong Area and in 2010 was promoted to VP, Head of Regulatory Center of Excellence, Company Representative having overall responsibility for the registration of drug and vaccine products. Prior to GSK, he was Medical Director, Global Medical Expert at Bayer-Schering Pharma Asia Pacific Area and from 2001-2005 was Medical Director at Sanofi China. Dr. Chen was co-author of various published articles and has presented at many international conferences. Dr. Chen received his medical degree from Shandong Medical University, China and received his Ph.D. in Clinical Pharmacology from the Royal Adelaide Hospital, University of Adelaide, Australia in 1989.

Tak Mak

Dr. Tak W. Mak, Ph.D., serves as Director of CASI Pharmaceuticals, Inc. He has been the Director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Hospital since 2004 and a University Professor in the Department of Medical Biophysics and Department of Immunology, University of Toronto, since 1984 and Professor in the Department of Medicine, University of Toronto, since 2008. Dr. Mak’s vast career includes serving as Vice President of Research at Amgen, Inc. and Director of the Amgen Institute in Toronto from 1993-2002, and is best known as the leading scientist of the group that first cloned the genes of the human T cell antigen receptor. Dr. Mak is an Officer of the Order of Canada, and has been elected a Foreign Associate of the National Academy of Sciences (USA), a Foreign Associate of the American Academy of Arts and Sciences, as well as a Fellow of the Royal Society of London (UK). He was awarded the Order of Ontario and has won international recognition in the form of the Emil von Behring Prize, the King Faisal Prize for Medicine, the Gairdner Foundation International Award, the Sloan Prize of the General Motors Cancer Foundation, the Novartis Prize in Immunology and the Paul Ehrlich Prize and Ludwig Darmstaedter Prize of Germany. Dr. Mak’s past and current ground-breaking medical research and his significant experience as a leader in pharmaceutical companies and research institutes provides significant insight in helping the Board of Directors formulate corporate strategies impacting the Company’s science, research and clinical development.

Rajesh Shrotriya

Dr. Rajesh C. Shrotriya is Director of the Company, effective September 22, 2014. He is currently the Chairman and Chief Executive Officer of Spectrum . Dr. Shrotriya joined Spectrum in 2000 as President and Chief Operating Officer and was appointed Chief Executive Officer in August 2002. In this capacity he has spearheaded major changes in business strategy and coordinated structural reorganization culminating in the formation of Spectrum Pharmaceuticals, Inc. Prior to joining Spectrum, Dr. Shrotriya was Executive Vice President and Chief Scientific Officer for SuperGen, Inc. and Vice President, Medical Affairs and Vice President, Chief Medical Officer at MGI Pharma, Inc. For 18 years he held various positions at Bristol-Myers Squibb Company, the most recent being Executive Director Worldwide CNS Clinical Research. Dr. Shrotriya’s significant leadership experience in the biopharmaceutical sector, along with his experience as a physician and his expertise in drug development, make him well-qualified to serve on our Board of Directors.

James Huang

Mr. James Z. Huang is an Independent Director of CASI Pharmaceuticals, Inc. He has been managing partner of Kleiner Perkins Caufield Byers China and general partner of KPCB China Fund II, LP since June 2011. Prior to Kleiner Perkins, from 2010 to 2011, Mr. Huang was managing partner at Vivo Ventures LLC, a venture capital firm specializing in life science investments. Mr. Huang has over 20 years of experience in the pharmaceutical and biopharmaceutical industry. During this time, he has held senior roles in business development, sales, marketing and R&D with Anesiva, Inc., Tularik Inc., GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. Mr. Huang received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkley. Mr. Huang’s deep experience and numerous contacts with a large number of life science companies, extensive industry knowledge in both U.S. and China, business development expertise, coupled with his financial background, provides significant abilities to guide the Company as a board member as well as serving as Chair of the Audit Committee and as Chair of the Compensation Committee.

Franklin Salisbury

Mr. Franklin C. Salisbury, Jr., is an Independent Director of CASI Pharmaceuticals, Inc. Since 1998, Mr. Salisbury has served as President of the National Foundation for Cancer Research (NFCR) where numerous research consortia and collaborations among research hospitals and pharmaceutical companies were launched under his leadership. Mr. Salisbury holds a B.A. in economics from Yale in 1978, a Masters of Arts degree from the University of Chicago, and a M.Div. from Yale Divinity School. He also earned his J.D. from the University of Georgia in 1992.

Y. Alexander Wu

Dr. Y. Alexander Wu, Ph.D., is an Independent Director of CASI Pharmaceuticals, Inc. He is CEO of Crown Bioscience, Inc., a drug discovery and pre-clinical research organization in the oncology sector with over 300 employees, he co-founded in 2006. Before Crown Bioscience, from 2004 to 2006, Alex was chief business officer of Starvax International Inc., a biopharmaceutical R&D company focusing on the development of novel therapeutic drugs for the treatment of infectious disease and cancer. Prior to Starvax, from 2001 to 2004, he was the Head of Asian Operations with Burrill & Company, a life science venture capital and merchant bank. Dr. Wu also co-founded and was chief operating officer of Unimicro Technologies, a life science instrumentation company. Dr. Wu started his career with Hoffmann-La Roche, where he was manager of business development and strategic planning. Dr. Wu obtained his B.S. in biochemistry from Fudan University, China, a M.S. in Biochemistry from the University of Illinois, and a Ph.D. in molecular cell biology and MBA from the University of California, Berkeley. Dr. Wu’s experience in the biopharmaceutical industry and research in the oncology and small molecule areas, practical experience as a senior executive operating in U.S. and China, and entrepreneurial vision makes him uniquely qualified to serve as a Director, as well as a member of the Compensation Committee and Audit Committee.

Basic Compensation